Abstract
Olanzapine is a new antipsychotic agent with serotonin/dopamine antagonism action. Efficacy in treating overall psychopathology in acute schizophrenia as measured by the BPRS0-6 total score was demonstrated at 10 mg/day versus placebo; at doses in a 5-20 mg/day range, olanzapine was comparable or superior to haloperidol. Superior efficacy for negative and depressive symptoms was shown in comparison to haloperidol. Olanzapine has a favorable acute and tardive extrapyramidal symptom profile relative to haloperidol and caused substantially less elevation of serum prolactin. Dose- related weight gain and asymptomatic mild transaminase elevations occurred in olanzapine-treated patients.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 45-49 |
| Number of pages | 5 |
| Journal | Journal of Clinical Psychiatry |
| Volume | 58 |
| Issue number | SUPPL. 10 |
| State | Published - Aug 20 1997 |
| Externally published | Yes |
ASJC Scopus subject areas
- Psychiatry and Mental health
UN SDGs
This output contributes to the following Sustainable Development Goal(s)
